Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis

References

• Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19;327(21):1478–1484.
   PubMed Web of Science ®Google Scholar
• Czyz A, Lojko-Dankowska A, Dytfeld D, et al. Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience. Med Oncol. 2013;30(3):611. doi:10.1007/s12032-013-0611-y.
   PubMed Web of Science ®Google Scholar
• Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. J Clin Oncol. 2002 Jan 1;20(1):221–230.
   PubMed Web of Science ®Google Scholar
• Radman I, Basic N, Labar B, et al. Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin’s disease (Croatian experience). Ann Oncol. 2002 Oct;13(10):1650–1655.
   PubMed Web of Science ®Google Scholar
• Sirohi B, Cunningham D, Powles R, et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol. 2008 Jul;19(7):1312–1319. doi:10.1093/annonc/mdn052.
   PubMed Web of Science ®Google Scholar
• Rancea M, Monsef I, Von Tresckow B, et al. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database Syst Rev. 2013;6:CD009411. doi:10.1002/14651858.CD004158.pub2.
   PubMedGoogle Scholar
• Younes A, Yasothan U, Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov. 2012 Jan;11(1):19–20. doi:10.1038/nrd3629.
   PubMed Web of Science ®Google Scholar
• Sutherland MS, Sanderson RJ, Gordon KA, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem. 2006 Apr 14;281(15):10540–10547.
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458–1465.
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012 Jun 20;30(18):2183–2189. doi:10.1200/JCO.2011.38.0410.
   PubMed Web of Science ®Google Scholar
• Ried K. Interpreting and understanding meta-analysis graphs–a practical guide. Aust Fam Physician. 2006;35(8):635–638.
   PubMedGoogle Scholar
• Haidich AB. Meta-analysis in medical research. Hippokratia. 2010 Dec;14(Suppl 1):29–37.
   PubMed Web of Science ®Google Scholar
• Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012 Jan 1;18(1):248–255.
   PubMed Web of Science ®Google Scholar
• Sasse S, Rothe A, Goergen H, et al. Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma. 2013 Oct;54(10):2144–2148. doi:10.3109/10428194.2013.775434.
   PubMed Web of Science ®Google Scholar
• Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012 Jun 28;119(26):6379–6381.
   PubMed Web of Science ®Google Scholar
• Garciaz S, Coso D, Peyrade F, et al. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin’s lymphoma. Hematol Oncol. 2014;32(4):187–191. doi:10.1002/hon.2119.
   PubMed Web of Science ®Google Scholar
• Yang Q-M, Hong JY, Ko YH, et al. Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia. Onco Targets Ther. 2014;7:1717–1722. doi:10.2147/OTT.S67380.
   PubMed Web of Science ®Google Scholar
• Salihoglu A, Elverdi T, Karadogan I, et al. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. Ann Hematol. 2015 Mar;94(3):415–420. doi:10.1007/s00277-014-2215-9.
   PubMed Web of Science ®Google Scholar
• Monjanel H, Deville L, Ram-Wolff C, et al. Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients. Br J Haematol. 2014 Jul;166(2):306–308. doi:10.1111/bjh.12849.
   PubMed Web of Science ®Google Scholar
• Gibb A, Jones C, Bloor A, et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica. 2013;98(4):611–614. doi:10.3324/haematol.2012.069393.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Viviani S, Anastasia A, et al. Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica. 2013;98(8):1232–1236. doi:10.3324/haematol.2012.083048.
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Fanale M, Advani R, et al. Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies. Oncologist. 2012;17(8):1073–1080. doi:10.1634/theoncologist.2012-0133.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Schoder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015 Mar;16(3):284–292. doi:10.1016/S1470-2045(15)70013-6.
   PubMed Web of Science ®Google Scholar
• Ogura M, Tobinai K, Hatake K, et al. Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci. 2014;105(7):840–846. doi:10.1111/cas.12435.
   PubMed Web of Science ®Google Scholar
• Chen RW, Palmer J, Martin P, et al. Results of a phase II trial of brentuximab vedotin as first line salvage therapy in relapsed/refractory HL prior to AHCT. ASH. 2014;2014:#501.
   Google Scholar
• Houk A, Gopal AK, Libby EN, et al. Prediction of progression-free survival with brentuximab vedotin therapy for relapsed Hodgkin lymphoma: a retrospective analysis. Blood. 2014Dec6;124(21):#3086.
   Web of Science ®Google Scholar
• Anderlini P, Saliba RM, Ledesma C, et al. Reduced-intensity conditioning (RIC) and allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory hodgkin lymphoma (HL) in the brentuximab vedotin era: favorable overall and progression-free survival (OS/PFS) with low transplant-related mortality (TRM). Blood. 2013 November 15;122(21):#410. doi:10.1182/blood-2012-12-471029.
   Web of Science ®Google Scholar
• Onishi M, Holmberg L, Shustov AR, et al. Brentuximab vedotin administered to platinum-refractory transplant naïve Hodgkin lymphoma patients can increase the proportion achieving FDG-PET negative status. Blood. 2013 Nov 15;122(21):#2106. doi:10.1182/blood-2012-12-471029.
   Web of Science ®Google Scholar
• Carlo-Stella C, Ricci F, Dalto S, et al. Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. Oncologist. 2015 Mar;20(3):323–328. doi:10.1634/theoncologist.2014-0420.
   PubMed Web of Science ®Google Scholar
• Perrot AMH, Bouabdallah R. Brentuximab vedotin as single agent in refractory or relapsed CD30-positive hodgkin lymphoma: the French name patient program experience in 241 patients. Haematologica. 2014;99(suppl1):Abstract S1293:498.5
   Google Scholar
• Gopal AK, Ramchandren R, O’Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012 Jul 19;120(3):560–568.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7:24. doi:10.1186/1756-8722-7-24.
   PubMed Web of Science ®Google Scholar
• Kahraman D, Theurich S, Rothe A, et al. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma. Leuk Lymphoma. 2014;55(4):811–816. doi:10.3109/10428194.2013.819575.
   PubMed Web of Science ®Google Scholar
• Bonthapally V, Wu E, Macalalad A, et al. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data. Curr Med Res Opin. 2015 May;31(5):993–1001. doi:10.1185/03007995.2015.1030378.
   PubMed Web of Science ®Google Scholar
• Perrot A, Monjanel H, Bouabdallah R, et al. Brentuximab vedotin as single agent in refractory or relapsed CD30-positive Hodgkin lymphoma: the French name patient program experience in 241 patients. Clin Adv Hematol Oncol. 2014;12(8Suppl 16):4–5.
   Google Scholar
• Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015 Feb 19;125(8):1236–1243.
   PubMed Web of Science ®Google Scholar
• Chen R, Gopal AK, Smith SE, et al. Five-year survival data demonstrating durable responses from a pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. ASH. 2015:126;Abstract 2736
   Google Scholar
• Validire P, Ferme C, Brice P, et al. A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin’s lymphoma patients. Anticancer Drugs. 2008 Mar;19(3):309–315.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol. 2007 Jun;18(6):1071–1079. doi:10.1093/annonc/mdm090.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Hamlin PA Jr., Perales M-A, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31(4):456–460. doi:10.1200/JCO.2012.45.3308.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2015;385(9980):1853–1862. doi:10.1016/S0140-6736(15)60165-9.
   PubMed Web of Science ®Google Scholar
• Illidge T, Bouabdallah R, Chen R, et al. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma. 2015 Mar;56(3):703–710. doi:10.3109/10428194.2014.930852.
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015 Dec 24;126(26):2798–2804.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH. Preliminary efficacy and safety of brentuximab vedotin and AVD chemotherapy followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Clin Adv Hematol Oncol. 2015 Aug;13(8Suppl 9):4–5.
   PubMedGoogle Scholar